Pharmaceutical Contract Manufacturing Market by Service (Drug Development, Pharmaceutical (API, FDF - Parenteral, Tablet, Capsule), Biologics (API, FDF), Packaging & Labelling, Fill-finish), Molecule (Small, Large (ADC, CGT)) - Global Forecast to 2030

icon1
USD 311.95 BN
MARKET SIZE, 2030
icon2
CAGR 8.2%
(2025-2030)
icon3
527
REPORT PAGES
icon4
620
MARKET TABLES

OVERVIEW

pharmaceutical-contract-manufacturing-market Overview

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

The global pharmaceutical contract manufacturing market is estimated to be USD 209.90 billion in 2025 and reach USD 311.95 billion by 2030, with a CAGR of 8.2% from 2025 to 2030. The pharmaceutical contract manufacturing market is expected to get a boost due to the GLP-1 capacity crunch, the increase in ADC development, the loss of patent expiries, and the increase in demand for biosimilars.

KEY TAKEAWAYS

  • By Region
    The North America peptide synthesis market accounted for a 40.3% revenue share in 2024.
  • By Services
    By Services, the drug development services segment is expected to register the highest CAGR of 12.2%.
  • By Molecule
    By Molecule, the large molecule segment will grow the fastest during the forecast period.
  • By End user
    By end user, the big pharmaceutical companies segment is expected to dominate the market, growing at the highest CAGR of 8.7%.
  • competitive landscape
    Thermo Fisher Scientific Inc, Lonza , Catalent, Inc were identified as some of the star players in the cell counting market (global), given their strong market share and product footprint.

The pharmaceutical contract manufacturing market is undergoing a significant transformation driven by advancements in technology, evolving regulatory frameworks, and shifting client demands. The adoption of continuous manufacturing, single-use bioreactor systems, and advanced process analytics is enabling greater efficiency, scalability, and cost-effectiveness in drug production. The rise of cell and gene therapies is prompting CDMOs to invest in specialized viral vector manufacturing, automated fill-finish systems, and high-containment facilities to meet stringent quality and biosafety standards

TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS

The pharmaceutical contract manufacturing market is undergoing major transformation driven by rapid expansion of biologics, sterile injectables, and advanced therapies. Rising complexity in drug pipelines, demand for speed-to-market, and pressure to lower production costs are accelerating the shift toward outsourced GMP manufacturing. At the same time, evolving regulatory expectations for data integrity, quality consistency, and global supply chain resilience are reshaping CDMO operations. Technology disruptions such as continuous manufacturing, single-use bioprocessing, automation, and AI-driven quality control are enabling faster scale-up, higher batch reliability, and reduced production risk. These developments are pushing pharma companies toward strategic outsourcing partnerships and end-to-end CDMO solutions, driving demand for next-generation contract manufacturing capabilities.

pharmaceutical-contract-manufacturing-market Disruptions

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

MARKET DYNAMICS

Drivers
Impact
Level
  • GLP-1 capacity crunch
  • Increasing development and manufacturing of antibody drug conjugates
RESTRAINTS
Impact
Level
  • Pricing pressure on innovator drugs
  • Growing penetration of generics and biosimilars
OPPORTUNITIES
Impact
Level
  • Rising demand for cell and gene therapies
  • Growing inclination toward one-stop-shop model
CHALLENGES
Impact
Level
  • Global trade instability and insourcing

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

Driver: GLP-1 capacity crunch

Growing global demand for GLP-1 drugs is creating a significant manufacturing capacity crunch, pushing pharmaceutical companies to rely heavily on CDMOs. Limited in-house biologics and peptide production capabilities, long scale-up timelines, and supply pressures are driving outsourced GMP manufacturing to ensure continuous supply and rapid market expansion.

Restraint: Pricing pressure on innovator drugs

Intensifying pricing pressure on innovative drugs is driving pharmaceutical companies to seek cost-efficient manufacturing models, accelerating reliance on CDMOs. As payers demand lower prices and governments tighten reimbursement, drug makers increasingly outsource production to reduce operational costs, optimize supply chains, and maintain profitability across high-value therapeutic portfolios.

Opportunity: Rising demand for cell and gene therapies

Rising demand for cell and gene therapies presents a major opportunity for the pharmaceutical CDMO market. As advanced therapies require specialized GMP facilities, viral vector capacity, and complex manufacturing expertise, drug developers increasingly depend on CDMOs to scale production. This surge enables CDMOs to expand high-value capabilities and secure long-term strategic partnerships.

Challenge:Global trade instability and insourcing

Global trade instability is creating a challenge for the pharmaceutical CDMO market, disrupting supply chains for APIs, raw materials, and critical components. Fluctuating tariffs, geopolitical tensions, and import–export restrictions increase production risks and costs, pushing companies to reassess sourcing strategies, diversify manufacturing partners, and strengthen regional CDMO networks.

pharmaceutical-contract-manufacturing-market: COMMERCIAL USE CASES ACROSS INDUSTRIES

COMPANY USE CASE DESCRIPTION BENEFITS
AstraZeneca partners with WuXi Biologics for commercial-scale manufacturing of monoclonal antibodies and biologics to meet global demand for oncology and respiratory therapies. Secures large-volume, multi-site commercial supply and ensures rapid global distribution in high-demand market
Eli Lilly uses Cipla’s India-based CDMO facilities for commercial manufacturing of insulin formulations to supply emerging markets at scale. Expands manufacturing capacity in cost-efficient regions and strengthens supply reliability for chronic disease therapies.
Teva relies on Recipharm for commercial production of inhalation and respiratory medicines, using Recipharm’s specialized device-plus-drug manufacturing expertise Access to advanced inhalation device technology and faster commercial rollout for complex combination products

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

MARKET ECOSYSTEM

The pharmaceutical CDMO market ecosystem consists of API and finished-dosage manufacturers (Catalent, Lonza), biologics and advanced therapy CDMOs (Samsung Biologics, WuXi Biologics), and specialized service providers for sterile injectables, HPAPIs, and cell & gene therapy production. These players supply end-to-end development, scale-up, and GMP manufacturing services supporting pharma, biotech, generics, and virtual pharma companies. Demand is driven by complex drug pipelines, rising biologics production needs, and the shift toward outsourcing to reduce cost and accelerate time-to-market. Collaboration across CDMOs, technology providers, and drug developers enables advances in automation, single-use bioprocessing, digital quality systems, and global supply resilience, supporting the market’s expansion and transition toward integrated, high-value manufacturing partnerships.

pharmaceutical-contract-manufacturing-market Ecosystem

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

MARKET SEGMENTS

pharmaceutical-contract-manufacturing-market Segments

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

Pharmaceutical Contract Manufacturing Market, By Service

As of 2024, pharmaceutical manufacturing services account for the largest share of the pharmaceutical CDMO market and are expected to maintain this lead through 2025. This dominance is driven by rising demand for large-scale GMP production of APIs, biologics, sterile injectables, and complex formulations. Unlike development services, manufacturing requires significant capacity, specialized facilities, and long-term commercial supply agreements, ensuring consistent revenue. The accelerating shift toward outsourcing and the growing volume of biologics and high-potency drugs further reinforce manufacturing services as the core revenue-generating segment of the CDMO market.

Pharmaceutical Contract Manufacturing Market, By Molecule

As of 2024, large molecules dominate the molecule segment of the pharmaceutical CDMO market and are expected to maintain their lead through 2025. Growing demand for biologics, monoclonal antibodies, and advanced therapies requires specialized GMP facilities, high-complexity manufacturing, and significant capacity investments—capabilities increasingly sourced from CDMOs. The rapid expansion of biologics pipelines and rising outsourcing by pharma and biotech companies further reinforce large molecules as the leading and fastest-growing segment.

Pharmaceutical Contract Manufacturing Market, By End User

As of 2024, big pharmaceutical companies dominate the end-user segment of the pharmaceutical CDMO market and are expected to maintain their lead through 2025. Their dominance is driven by the large volume of commercial-scale production they outsource, growing biologics and injectable portfolios, and the need to optimize cost, capacity, and supply chain resilience. Strategic partnerships, long-term manufacturing contracts, and expansion into complex modalities further reinforce big pharma as the largest and most influential end-user group in the CDMO ecosystem.

REGION

Asia Pacific to be fastest-growing region in global pharmaceutical contract manufacturing market during forecast period

The Asia Pacific pharmaceutical CDMO market is projected to grow at the fastest rate during the forecast period, driven by rapid expansion in biopharmaceutical production, sterile injectable manufacturing, and advanced therapy capabilities. Countries such as China, India, South Korea, and Singapore are heavily investing in GMP facilities, automation, and large-scale biologics and API manufacturing infrastructure. Rising clinical trial activity, government support for pharmaceutical innovation, and the strong presence of cost-efficient CDMOs make the region an attractive outsourcing hub for global pharma. These developments collectively position Asia Pacific as the fastest-growing region in the global CDMO market.

pharmaceutical-contract-manufacturing-market Region

pharmaceutical-contract-manufacturing-market: COMPANY EVALUATION MATRIX

In the pharmaceutical CDMO market matrix, Thermo Fisher Scientific (Star) leads with a strong market share and an extensive end-to-end service portfolio spanning API manufacturing, biologics, sterile injectables, cell and gene therapy, and commercial-scale supply. Its global GMP network, advanced technologies, and integrated development-to-manufacturing capabilities position it as the preferred partner for both large pharma and emerging biotech companies.Cambrex corporation (Emerging Leader) is steadily gaining traction by expanding its specialized strengths in small-molecule API manufacturing, oral solid dose development, and clinical-to-commercial supply solutions. While Thermo Fisher maintains dominance through scale, diversification, and global infrastructure, Almac shows strong potential to move toward the leaders quadrant as demand rises for high-quality, flexible, and specialized CDMO services.

pharmaceutical-contract-manufacturing-market Evaluation Metrics

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

KEY MARKET PLAYERS

MARKET SCOPE

REPORT METRIC DETAILS
Market Size in 2024 (Value) USD 193.52 Billion
Market Forecast in 2030 (Value) USD 311.95 Billion
Growth Rate CAGR of 8.2% from 2025-2030
Years Considered 2023-2030
Base Year 2024
Forecast Period 2025-2030
Units Considered Value (USD Billion)
Report Coverage Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Segments Covered
  • By Services :
    • Pharmaceutical Manufacturing Services
    • Drug Development Services
    • Biologics Manufacturing Services
    • Packaging & Labelling Services
    • Fill-finish Services
    • Other Services
  • By Molecules:
    • Small molecules
    • Large Molecules
  • By end users:
    • Big pharmaceutical companies
    • Small & medium-sized pharmaceutical companies
    • Generic pharmaceutical companies
    • Others (Academic Institutes
    • CROs)
Regions Covered North America, Asia Pacific, Europe, South America, Middle East and Africa

WHAT IS IN IT FOR YOU: pharmaceutical-contract-manufacturing-market REPORT CONTENT GUIDE

pharmaceutical-contract-manufacturing-market Content Guide

DELIVERED CUSTOMIZATIONS

We have successfully delivered the following deep-dive customizations:

CLIENT REQUEST CUSTOMIZATION DELIVERED VALUE ADDS
Capacity & Capability Mapping Detailed mapping of CDMO manufacturing capacity by API type, biologics, HPAPI, sterile injectables, and advanced therapies Improves supply planning and reduces outsourcing risks
Supply Chain & Risk Assessment Mapping of supply chain vulnerabilities including API sourcing, geopolitics, and logistics bottlenecks Strengthens business continuity planning

RECENT DEVELOPMENTS

  • October 2024 : Thermo Fisher Scientific Inc. launched accelerator drug development, which offered an end-to-end suite of drug development and clinical services spanning drug substance and drug product manufacturing for small molecule, large molecule, and advanced therapies, clinical supply, clinical research, and commercialization.
  • March 2024 : Lonza acquired theGenentech large-scale biologics manufacturing site in Vacaville, California (US) from Roche.
  • June 2023 : Lonza and Vertex collaborated to support the manufacture of Vertex's portfolio of investigational stem cell- derived, fully differentiated insulin-producing islet cell therapies for people with T1D, currently focusing on the VX- 880 and VX-264 programs that are in clinical trials.

 

Table of Contents

Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.

TITLE
PAGE NO
INTRODUCTION
42
RESEARCH METHODOLOGY
47
EXECUTIVE SUMMARY
60
PREMIUM INSIGHTS
66
MARKET OVERVIEW
This Section Covers the Market Dynamics, and Upcoming Trends Shaping the Future Growth of the Pharmaceutical Contract Manufacturing Market.
71
  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    DRIVERS
    - GLP-1 capacity crunch
    - Increasing development and manufacturing of antibody drug conjugates
    - Loss of exclusivity of blockbuster biologics
    - Increasing complexity of injectable drug formats
    RESTRAINTS
    - Pricing pressure on innovator drugs
    - Growing penetration of generics and biosimilars
    - Strict regulatory compliance
    - Risk in advanced therapies pipeline
    OPPORTUNITIES
    - Rising demand for cell and gene therapies
    - Growing inclination toward one-stop-shop model
    - Market expansion in emerging countries
    - Booming radiopharmaceutical and nuclear medicine segment
    CHALLENGES
    - Global trade instability and insourcing
  • 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
  • 5.4 PRICING ANALYSIS
    INDICATIVE PRICING ANALYSIS, BY SERVICE
    INDICATIVE PRICING ANALYSIS, BY REGION
    COMPARISON OF CDMO PRICING MODELS
  • 5.5 VALUE CHAIN ANALYSIS
  • 5.6 SUPPLY CHAIN ANALYSIS
  • 5.7 ECOSYSTEM ANALYSIS
    MANUFACTURING SITE, EXPANSION, AND CAPEX TREND OF KEY CDMOS
  • 5.8 INVESTMENT AND FUNDING SCENARIO
  • 5.9 TECHNOLOGY ANALYSIS
    KEY TECHNOLOGIES
    - Single-use bioprocessing systems
    - Continuous manufacturing
    - Advanced formulation technologies
    COMPLEMENTARY TECHNOLOGIES
    - High-performance liquid chromatography
    - Mass spectrometry
    - Next-generation sequencing
    - Automation and robotics
    - Process analytical technology
    ADJACENT TECHNOLOGIES
    - 3D printing
    - Artificial intelligence and machine learning
  • 5.10 PATENT ANALYSIS
  • 5.11 KEY CONFERENCES AND EVENTS, 2025–2026
  • 5.12 REGULATORY LANDSCAPE
    REGULATORY SCENARIO
    REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.13 PORTER’S FIVE FORCES ANALYSIS
    BARGAINING POWER OF SUPPLIERS
    BARGAINING POWER OF BUYERS
    THREAT OF NEW ENTRANTS
    THREAT OF SUBSTITUTES
    INTENSITY OF COMPETITIVE RIVALRY
  • 5.14 KEY STAKEHOLDERS AND BUYING CRITERIA
    KEY STAKEHOLDERS IN BUYING PROCESS
    BUYING CRITERIA
  • 5.15 UNMET NEEDS OF END USERS
    CAPACITY AND TIMELY ACCESS
    COST EFFICIENCY AND FLEXIBILITY
    END-TO-END INTEGRATED SERVICES
    ADVANCED MODALITY EXPERTISE
    QUALITY AND REGULATORY CONSISTENCY
  • 5.16 ABBREVIATED NEW DRUG APPLICATION (ANDA) APPROVALS
  • 5.17 IMPACT OF AI/GEN AI ON PHARMACEUTICAL CONTRACT MANUFACTURING MARKET
    INTRODUCTION
    MARKET POTENTIAL OF AI/GEN AI
    AI USE CASES
    KEY COMPANIES IMPLEMENTING AI/GEN AI
  • 5.18 IMPACT OF 2025 US TARIFFS ON PHARMACEUTICAL CONTRACT MANUFACTURING MARKET
    INTRODUCTION
    KEY TARIFF RATES
    PRICE IMPACT ANALYSIS
    IMPACT ON COUNTRY/REGION
    - US
    - Europe
    - Asia Pacific
    IMPACT ON END-USE INDUSTRIES
PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE
Market Assessment for Pharmaceutical Contract Manufacturing Market, By Service: Market Sizing (2023-2030) and Forecast to 2030 (Value USD Million)
126
  • 6.1 INTRODUCTION
  • 6.2 PHARMACEUTICAL MANUFACTURING SERVICES
    PHARMACEUTICAL API MANUFACTURING SERVICES
    - Rising cases of patent expiry to fuel market
    PHARMACEUTICAL FDF MANUFACTURING SERVICES
    - Parenteral manufacturing services
    - Tablet manufacturing services
    - Capsule manufacturing services
    - Oral liquid manufacturing services
    - Semi-solid manufacturing services
    - Other FDF manufacturing services
  • 6.3 DRUG DEVELOPMENT SERVICES
    INCREASING COST OF DRUG DISCOVERY AND DEVELOPMENT TO EXPEDITE GROWTH
  • 6.4 BIOLOGICS MANUFACTURING SERVICES
    BIOLOGICS API MANUFACTURING SERVICES
    - Rising investments in single-use production capacities to bolster growth
    BIOLOGICS FDF MANUFACTURING SERVICES
    - Growing demand for generic medicines and biologics to fuel market
  • 6.5 PACKAGING & LABELING SERVICES
    INCREASING COMPLEXITY AND STRINGENCY OF REGULATORY REQUIREMENTS FOR DRUG SAFETY AND EFFICACY TO FAVOR GROWTH
  • 6.6 FILL-FINISH SERVICES
    SURGE IN DEMAND FOR BIOLOGICS AND COMPLEX INJECTABLE THERAPIES TO BOOST MARKET
  • 6.7 OTHER SERVICES
PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE
Market Assessment for Pharmaceutical Contract Manufacturing Market, By Molecule: Market Sizing (2023-2030) and Forecast to 2030 (Value USD Million)
185
  • 7.1 INTRODUCTION
  • 7.2 SMALL MOLECULES
    HIGH-POTENCY SMALL MOLECULES
    - Increasing adoption of high-potency small molecules for treating oncology, rare diseases, and other diseases to aid growth
    OLIGONUCLEOTIDE & SYNTHETIC PEPTIDES
    - Growing focus on next-gen therapies to drive market
    RADIOPHARMACEUTICAL MOLECULES
    - Advances in isotope production, radiolabeling chemistry, and theranostic approaches to boost market
    OTHER SMALL MOLECULES
  • 7.3 LARGE MOLECULES
    MONOCLONAL ANTIBODIES
    - Rising use of mAbs in managing cancer, autoimmune disorders, and osteoporosis to spur growth
    CELL & GENE THERAPIES
    - Emerging treatments for previously untreatable genetic and rare diseases to boost market
    ANTIBODY DRUG CONJUGATES
    - Growing need for precision medicines to fuel market
    VACCINES
    - Growing threat of infectious disease outbreaks to drive market
    THERAPEUTIC PEPTIDES & PROTEINS
    - Increasing research in genomics to support growth
    OTHER LARGE MOLECULES
PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER
End User-specific Assessment for Pharmaceutical Contract Manufacturing Market: Market Sizing (2023-2030) and Forecast to 2030 (Value USD Million)
229
  • 8.1 INTRODUCTION
  • 8.2 BIG PHARMACEUTICAL COMPANIES
    PRICING PRESSURE IN PHARMACEUTICAL INDUSTRY TO CONTRIBUTE TO GROWTH
  • 8.3 SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES
    NEED TO SAVE IN-HOUSE DRUG MANUFACTURING COST TO FOSTER GROWTH
  • 8.4 GENERIC PHARMACEUTICAL COMPANIES
    FAVORABLE GOVERNMENT SUPPORT FOR ADOPTION OF GENERIC DRUGS TO PROPEL MARKET
  • 8.5 OTHER END USERS
PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY REGION
Region and Country-level Assessment for Pharmaceutical Contract Manufacturing Market: Market Sizing (2023-2030) and Forecast to 2030 (Value USD Million)
245
  • 9.1 INTRODUCTION
  • 9.2 NORTH AMERICA
    MACROECONOMIC OUTLOOK FOR NORTH AMERICA
    US
    - High clinical trial and drug discovery activities to foster growth
    CANADA
    - Favorable government support and increased focus on R&D activities to sustain growth
  • 9.3 EUROPE
    MACROECONOMIC OUTLOOK FOR EUROPE
    GERMANY
    - Free drug-pricing policy and high pharmaceutical investments to speed up growth
    UK
    - Favorable R&D funding scenario to augment growth
    FRANCE
    - Booming life science research and growing generics market to drive market
    ITALY
    - Rising commercial drug development and increasing life science R&D to favor growth
    SWITZERLAND
    - Rapid growth as global pharmaceutical manufacturing hub to drive market
    POLAND
    - Universal health coverage and advanced government-supported medical infrastructure to encourage growth
    SPAIN
    - Growing pharmaceutical R&D expenditure and increasing outsourcing of trial phases to boost market
    REST OF EUROPE
  • 9.4 ASIA PACIFIC
    MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
    CHINA
    - Made in China 2025 initiative and high government drug development investments to aid growth
    JAPAN
    - High geriatric population and advanced pharmaceutical research to augment growth
    SOUTH KOREA
    - Increased biotech investments and developed pharma sector to propel market
    INDIA
    - Favorable industrial environment and lower labor costs to drive market
    AUSTRALIA
    - Strategic geographical location and stringent regulatory environment to foster growth
    REST OF ASIA PACIFIC
  • 9.5 LATIN AMERICA
    MACROECONOMIC OUTLOOK FOR LATIN AMERICA
    BRAZIL
    - Rapid patient enrolment and increased focus on advanced clinical trials to expedite growth
    MEXICO
    - Surge in pharmaceutical goods export to promote growth
    REST OF LATIN AMERICA
  • 9.6 MIDDLE EAST
    MACROECONOMIC OUTLOOK FOR MIDDLE EAST
    GCC COUNTRIES
    - Kingdom of Saudi Arabia (KSA)
    - UAE
    - Rest of GCC countries
    REST OF MIDDLE EAST
  • 9.7 AFRICA
    RISING PREVALENCE OF CHRONIC DISEASES TO FACILITATE GROWTH
    MACROECONOMIC OUTLOOK OF AFRICA
COMPETITIVE LANDSCAPE
This Section Covers Strategic Analysis of Key Players, Market Shares (%), Revenue Analysis (USD Million), Competitive Mapping and Benchmarking for Key Players and SMEs/Start-ups
391
  • 10.1 INTRODUCTION
  • 10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
  • 10.3 REVENUE SHARE ANALYSIS, 2020–2024
  • 10.4 MARKET SHARE ANALYSIS, 2024
  • 10.5 COMPANY VALUATION AND FINANCIAL METRICS
  • 10.6 BRAND/SERVICE COMPARISON
    THERMO FISHER SCIENTIFIC INC.
    LONZA
    WUXI BIOLOGICS AND WUXI APPTEC
    CATALENT, INC.
    SAMSUNG BIOLOGICS
  • 10.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
    STARS
    EMERGING LEADERS
    PERVASIVE PLAYERS
    PARTICIPANTS
    COMPANY FOOTPRINT: KEY PLAYERS, 2024
    - Company footprint
    - Region footprint
    - Service footprint
    - Molecule footprint
  • 10.8 COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024
    PROGRESSIVE COMPANIES
    RESPONSIVE COMPANIES
    DYNAMIC COMPANIES
    STARTING BLOCKS
    COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
    - Detailed list of key startups/SMEs
    - Competitive benchmarking of key startups/SMEs
  • 10.9 COMPETITIVE SCENARIO
    SERVICE LAUNCHES
    DEALS
    EXPANSIONS
COMPANY PROFILES
In-depth Profiling of Key Players and SMEs/Start-ups Operating in the Pharmaceutical Contract Manufacturing Market: Business Overview, Offerings, Recent Developments
419
  • 11.1 KEY PLAYERS
    THERMO FISHER SCIENTIFIC INC.
    - Business overview
    - Services offered
    - Recent developments
    - MnM view
    LONZA
    - Business overview
    - Services offered
    - Recent developments
    - MnM view
    CATALENT, INC.
    - Business overview
    - Services offered
    - Recent developments
    - MnM view
    WUXI APPTEC
    - Business overview
    - Services offered
    - Recent developments
    - MnM view
    WUXI BIOLOGICS
    - Business overview
    - Services offered
    - Recent developments
    SAMSUNG BIOLOGICS
    - Business overview
    - Services offered
    - Recent developments
    BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    - Business overview
    - Services offered
    - Recent developments
    EVONIK
    - Business overview
    - Services offered
    - Recent developments
    FUJIFILM HOLDINGS CORPORATION
    - Business overview
    - Services offered
    - Recent developments
    ABBVIE INC.
    - Business overview
    - Services offered
    - Recent developments
    SIEGFRIED HOLDING AG
    - Business overview
    - Services offered
    - Recent developments
    MERCK KGAA
    - Business overview
    - Services offered
    - Recent developments
    ALMAC GROUP
    - Business overview
    - Services offered
    - Recent developments
    CHARLES RIVER LABORATORIES
    - Business overview
    - Services offered
    - Recent developments
    ASYMCHEM INC.
    - Business overview
    - Services offered
    - Recent developments
    VETTER
    - Business overview
    - Services offered
    - Recent developments
    ALCAMI CORPORATION
    - Business overview
    - Services offered
    - Recent developments
    EUROFINS SCIENTIFIC
    - Business overview
    - Services offered
    - Recent developments
  • 11.2 OTHER PLAYERS
    PIRAMAL PHARMA SOLUTIONS
    SYNGENE INTERNATIONAL LIMITED
    CAMBREX CORPORATION
    JUBILANT PHARMANOVA LIMITED
    YUHAN CORPORATION
    PIERRE FABRE LABORATORIES
    PFIZER CENTREONE
    DELPHARM
    FRONTAGE LABS
    SHARP SERVICES, LLC
    GRAND RIVER ASEPTIC MANUFACTURING
    RECIPHARM AB
    PCI PHARMA SERVICES
    CURIA GLOBAL, INC.
    SIMTRA BIOPHARMA SOLUTIONS
    PORTON
    MABPLEX INTERNATIONAL CO. LTD.
    CELLARES
APPENDIX
513
  • 12.1 DISCUSSION GUIDE
  • 12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
  • 12.3 CUSTOMIZATION OPTIONS
  • 12.4 RELATED REPORTS
  • 12.5 AUTHOR DETAILS
LIST OF TABLES
 
  • TABLE 1 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: INCLUSIONS AND EXCLUSIONS
  • TABLE 2 IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS
  • TABLE 3 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: RISK ANALYSIS
  • TABLE 4 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: IMPACT ANALYSIS OF MARKET DYNAMICS
  • TABLE 5 GLP-1 PIPELINE, EXPECTED LAUNCH BY 2030
  • TABLE 6 ADC PIPELINE, EXPECTED LAUNCH BY 2030
  • TABLE 7 IMPENDING AND ONGOING PATENT EXPIRIES OF BLOCKBUSTER BIOLOGICS, 2023–2035
  • TABLE 8 LIST OF RECENTLY APPROVED INJECTABLES, 2022–2024
  • TABLE 9 CELL & GENE THERAPY-SPECIFIC CDMO EXPANSIONS, 2023–2025
  • TABLE 10 CELL & GENE THERAPY PIPELINE, EXPECTED LAUNCH BY 2030
  • TABLE 11 INDICATIVE PRICING ANALYSIS, BY SERVICE
  • TABLE 12 INDICATIVE PRICING ANALYSIS, BY REGION
  • TABLE 13 PRICING MODELS FOR CDMO SERVICES
  • TABLE 14 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: ROLE OF COMPANIES IN SUPPLY CHAIN
  • TABLE 15 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: ROLE OF COMPANIES IN ECOSYSTEM
  • TABLE 16 MANUFACTURING SITES OF KEY CDMOS
  • TABLE 17 LIST OF SITE EXPANSIONS FOR KEY CDMOS, 2023–2025
  • TABLE 18 CAPEX FOR SELECTED PUBLICLY LISTED KEY CDMOS, 2021–2024 (USD MILLION)
  • TABLE 19 NUMBER OF PATENTS FILED IN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, 2014–2024
  • TABLE 20 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: KEY CONFERENCES AND EVENTS, 2025–2026
  • TABLE 21 REGULATORY SCENARIO, BY COUNTRY
  • TABLE 22 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 23 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 24 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 25 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 26 MIDDLE EAST: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 27 AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 28 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: PORTER’S FIVE FORCES ANALYSIS
  • TABLE 29 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF PHARMACEUTICAL CONTRACT MANUFACTURING SERVICES (%)
  • TABLE 30 BUYING CRITERIA FOR PHARMACEUTICAL CONTRACT MANUFACTURING, BY END USER
  • TABLE 31 US-ADJUSTED RECIPROCAL TARIFF RATES
  • TABLE 32 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD BILLION)
  • TABLE 33 PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 34 PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY REGION, 2023–2030 (USD BILLION)
  • TABLE 35 NORTH AMERICA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 36 EUROPE: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 37 ASIA PACIFIC: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 38 LATIN AMERICA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 39 MIDDLE EAST: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY REGION, 2023–2030 (USD BILLION)
  • TABLE 40 GCC COUNTRIES: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 41 PHARMACEUTICAL API MANUFACTURING SERVICES MARKET, BY REGION, 2023–2030(USD BILLION)
  • TABLE 42 NORTH AMERICA: PHARMACEUTICAL API MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030(USD BILLION)
  • TABLE 43 EUROPE: PHARMACEUTICAL API MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030(USD BILLION)
  • TABLE 44 ASIA PACIFIC: PHARMACEUTICAL API MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030(USD BILLION)
  • TABLE 45 LATIN AMERICA: PHARMACEUTICAL API MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030(USD BILLION)
  • TABLE 46 MIDDLE EAST: PHARMACEUTICAL API MANUFACTURING SERVICES MARKET, BY REGION, 2023–2030(USD BILLION)
  • TABLE 47 GCC COUNTRIES: PHARMACEUTICAL API MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030(USD BILLION)
  • TABLE 48 PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030(USD BILLION)
  • TABLE 49 PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY REGION, 2023–2030(USD BILLION)
  • TABLE 50 NORTH AMERICA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030(USD BILLION)
  • TABLE 51 EUROPE: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030(USD BILLION)
  • TABLE 52 ASIA PACIFIC: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030(USD BILLION)
  • TABLE 53 LATIN AMERICA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030(USD BILLION)
  • TABLE 54 MIDDLE EAST: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY REGION, 2023–2030(USD BILLION)
  • TABLE 55 GCC COUNTRIES: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030(USD BILLION)
  • TABLE 56 PARENTERAL MANUFACTURING SERVICES MARKET, BY REGION, 2023–2030 (USD BILLION)
  • TABLE 57 NORTH AMERICA: PARENTERAL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 58 EUROPE: PARENTERAL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 59 ASIA PACIFIC: PARENTERAL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 60 LATIN AMERICA: PARENTERAL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 61 MIDDLE EAST: PARENTERAL MANUFACTURING SERVICES MARKET, BY REGION, 2023–2030 (USD BILLION)
  • TABLE 62 GCC COUNTRIES: PARENTERAL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 63 TABLET MANUFACTURING SERVICES MARKET, BY REGION, 2023–2030 (USD BILLION)
  • TABLE 64 NORTH AMERICA: TABLET MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 65 EUROPE: TABLET MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 66 ASIA PACIFIC: TABLET MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 67 LATIN AMERICA: TABLET MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 68 MIDDLE EAST: TABLET MANUFACTURING SERVICES MARKET, BY REGION, 2023–2030 (USD BILLION)
  • TABLE 69 GCC COUNTRIES: TABLET MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 70 CAPSULE MANUFACTURING SERVICES MARKET, BY REGION, 2023–2030 (USD BILLION)
  • TABLE 71 NORTH AMERICA: CAPSULE MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 72 EUROPE: CAPSULE MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 73 ASIA PACIFIC: CAPSULE MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 74 LATIN AMERICA: CAPSULE MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 75 MIDDLE EAST: CAPSULE MANUFACTURING SERVICES MARKET, BY REGION, 2023–2030 (USD BILLION)
  • TABLE 76 GCC COUNTRIES: CAPSULE MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 77 ORAL LIQUID MANUFACTURING SERVICES MARKET, BY REGION, 2023–2030 (USD BILLION)
  • TABLE 78 NORTH AMERICA: ORAL LIQUID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 79 EUROPE: ORAL LIQUID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 80 ASIA PACIFIC: ORAL LIQUID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 81 LATIN AMERICA: ORAL LIQUID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 82 MIDDLE EAST: ORAL LIQUID MANUFACTURING SERVICES MARKET, BY REGION, 2023–2030 (USD BILLION)
  • TABLE 83 GCC COUNTRIES: ORAL LIQUID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 84 SEMI-SOLID MANUFACTURING SERVICES MARKET, BY REGION, 2023–2030 (USD BILLION)
  • TABLE 85 NORTH AMERICA: SEMI-SOLID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 86 EUROPE: SEMI-SOLID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 87 ASIA PACIFIC: SEMI-SOLID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 88 LATIN AMERICA: SEMI-SOLID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 89 MIDDLE EAST: SEMI-SOLID MANUFACTURING SERVICES MARKET, BY REGION, 2023–2030 (USD BILLION)
  • TABLE 90 GCC COUNTRIES: SEMI-SOLID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 91 OTHER FDF MANUFACTURING SERVICES MARKET, BY REGION, 2023–2030 (USD BILLION)
  • TABLE 92 NORTH AMERICA: OTHER FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 93 EUROPE: OTHER FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 94 ASIA PACIFIC: OTHER FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 95 LATIN AMERICA: OTHER FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 96 MIDDLE EAST: OTHER FDF MANUFACTURING SERVICES MARKET, BY REGION, 2023–2030 (USD BILLION)
  • TABLE 97 GCC COUNTRIES: OTHER FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 98 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR DRUG DEVELOPMENT SERVICES, BY REGION, 2023–2030 (USD BILLION)
  • TABLE 99 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR DRUG DEVELOPMENT SERVICES, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 100 EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR DRUG DEVELOPMENT SERVICES, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 101 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR DRUG DEVELOPMENT SERVICES, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 102 LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR DRUG DEVELOPMENT SERVICES, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 103 MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR DRUG DEVELOPMENT SERVICES, BY REGION, 2023–2030 (USD BILLION)
  • TABLE 104 GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR DRUG DEVELOPMENT SERVICES, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 105 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 106 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY REGION, 2023–2030 (USD BILLION)
  • TABLE 107 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 108 EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 109 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 110 LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 111 MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY REGION, 2023–2030 (USD BILLION)
  • TABLE 112 GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 113 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS API MANUFACTURING SERVICES, BY REGION, 2023–2030 (USD BILLION)
  • TABLE 114 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS API MANUFACTURING SERVICES, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 115 EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS API MANUFACTURING SERVICES, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 116 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS API MANUFACTURING SERVICES, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 117 LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS API MANUFACTURING SERVICES, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 118 MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS API MANUFACTURING SERVICES, BY REGION, 2023–2030 (USD BILLION)
  • TABLE 119 GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS API MANUFACTURING SERVICES, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 120 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS FDF MANUFACTURING SERVICES, BY REGION, 2023–2030 (USD BILLION)
  • TABLE 121 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS FDF MANUFACTURING SERVICES, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 122 EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS FDF MANUFACTURING SERVICES, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 123 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS FDF MANUFACTURING SERVICES, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 124 LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS FDF MANUFACTURING SERVICES, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 125 MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS FDF MANUFACTURING SERVICES, BY REGION, 2023–2030 (USD BILLION)
  • TABLE 126 GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS FDF MANUFACTURING SERVICES, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 127 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR PACKAGING & LABELING SERVICES, BY REGION, 2023–2030 (USD BILLION)
  • TABLE 128 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR PACKAGING & LABELING SERVICES, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 129 EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR PACKAGING & LABELING SERVICES, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 130 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR PACKAGING & LABELING SERVICES, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 131 LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR PACKAGING & LABELING SERVICES, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 132 MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR PACKAGING & LABELING SERVICES, BY REGION, 2023–2030 (USD BILLION)
  • TABLE 133 GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR PACKAGING & LABELING SERVICES, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 134 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR FILL-FINISH SERVICES, BY REGION, 2023–2030 (USD BILLION)
  • TABLE 135 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR FILL-FINISH SERVICES, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 136 EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR FILL-FINISH SERVICES, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 137 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR FILL-FINISH SERVICES, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 138 LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR FILL-FINISH SERVICES, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 139 MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR FILL- FINISH SERVICES, BY REGION, 2023–2030 (USD BILLION)
  • TABLE 140 GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR FILL-FINISH SERVICES, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 141 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER SERVICES, BY REGION, 2023–2030 (USD BILLION)
  • TABLE 142 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER SERVICES, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 143 EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER SERVICES, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 144 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER SERVICES, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 145 LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER SERVICES, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 146 MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER SERVICES, BY REGION, 2023–2030 (USD BILLION)
  • TABLE 147 GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER SERVICES, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 148 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE, 2023–2030 (USD BILLION)
  • TABLE 149 PHARMACEUTICAL MANUFACTURING SERVICES MARKET FOR SMALL MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 150 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY REGION, 2023–2030 (USD BILLION)
  • TABLE 151 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 152 EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 153 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 154 LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 155 MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY REGION, 2023–2030 (USD BILLION)
  • TABLE 156 GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 157 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR HIGH-POTENCY SMALL MOLECULES, BY REGION, 2023–2030 (USD BILLION)
  • TABLE 158 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR HIGH-POTENCY SMALL MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 159 EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR HIGH-POTENCY SMALL MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 160 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR HIGH-POTENCY SMALL MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 161 LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR HIGH-POTENCY SMALL MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 162 MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR HIGH-POTENCY SMALL MOLECULES, BY REGION, 2023–2030 (USD BILLION)
  • TABLE 163 GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR HIGH POTENCY SMALL MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 164 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OLIGONUCLEOTIDES AND SYNTHETIC PEPTIDES, BY REGION, 2023–2030 (USD BILLION)
  • TABLE 165 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OLIGONUCLEOTIDES AND SYNTHETIC PEPTIDES, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 166 EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OLIGONUCLEOTIDES AND SYNTHETIC PEPTIDES, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 167 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OLIGONUCLEOTIDES AND SYNTHETIC PEPTIDES, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 168 LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OLIGONUCLEOTIDES AND SYNTHETIC PEPTIDES, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 169 MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OLIGONUCLEOTIDES AND SYNTHETIC PEPTIDES, BY REGION, 2023–2030 (USD BILLION)
  • TABLE 170 GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OLIGONUCLEOTIDES AND SYNTHETIC PEPTIDES, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 171 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR RADIOPHARMACEUTICAL MOLECULES, BY REGION, 2023–2030 (USD BILLION)
  • TABLE 172 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR RADIOPHARMACEUTICAL MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 173 EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR RADIOPHARMACEUTICAL MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 174 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR RADIOPHARMACEUTICAL MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 175 LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR RADIOPHARMACEUTICAL MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 176 MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR RADIOPHARMACEUTICAL MOLECULES, BY REGION, 2023–2030 (USD BILLION)
  • TABLE 177 GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR RADIOPHARMACEUTICAL MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 178 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER SMALL MOLECULES, BY REGION, 2023–2030 (USD BILLION)
  • TABLE 179 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER SMALL MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 180 EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER SMALL MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 181 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER SMALL MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 182 LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER SMALL MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 183 MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER SMALL MOLECULES, BY REGION, 2023–2030 (USD BILLION)
  • TABLE 184 GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER SMALL MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 185 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 186 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY REGION, 2023–2030 (USD BILLION)
  • TABLE 187 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 188 EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 189 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 190 LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 191 MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY REGION, 2023–2030 (USD BILLION)
  • TABLE 192 GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 193 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2023–2030 (USD BILLION)
  • TABLE 194 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 195 EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 196 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 197 LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 198 MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2023–2030 (USD BILLION)
  • TABLE 199 GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 200 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR CELL & GENE THERAPIES, BY REGION, 2023–2030 (USD BILLION)
  • TABLE 201 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR CELL & GENE THERAPIES, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 202 EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR CELL & GENE THERAPIES, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 203 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR CELL & GENE THERAPIES, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 204 LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR CELL & GENE THERAPIES, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 205 MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR CELL & GENE THERAPIES, BY REGION, 2023–2030 (USD BILLION)
  • TABLE 206 GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR CELL & GENE THERAPIES, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 207 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR ANTIBODY DRUG CONJUGATES, BY REGION, 2023–2030 (USD BILLION)
  • TABLE 208 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR ANTIBODY DRUG CONJUGATES, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 209 EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR ANTIBODY DRUG CONJUGATES, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 210 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR ANTIBODY DRUG CONJUGATES, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 211 LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR ANTIBODY DRUG CONJUGATES, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 212 MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR ANTIBODY DRUG CONJUGATES, BY REGION, 2023–2030 (USD BILLION)
  • TABLE 213 GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR ANTIBODY DRUG CONJUGATES, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 214 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR VACCINES, BY REGION, 2023–2030 (USD BILLION)
  • TABLE 215 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR VACCINES, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 216 EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR VACCINES, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 217 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR VACCINES, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 218 LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR VACCINES, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 219 MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR VACCINES, BY REGION, 2023–2030 (USD BILLION)
  • TABLE 220 GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR VACCINES, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 221 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR THERAPEUTIC PEPTIDES & PROTEINS, BY REGION, 2023–2030 (USD BILLION)
  • TABLE 222 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR THERAPEUTIC PEPTIDES & PROTEINS, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 223 EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR THERAPEUTIC PEPTIDES & PROTEINS, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 224 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR THERAPEUTIC PEPTIDES & PROTEINS, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 225 LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR THERAPEUTIC PEPTIDES & PROTEINS, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 226 MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR THERAPEUTIC PEPTIDES & PROTEINS, BY REGION, 2023–2030 (USD BILLION)
  • TABLE 227 GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR THERAPEUTIC PEPTIDES & PROTEINS, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 228 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER LARGE MOLECULES, BY REGION, 2023–2030 (USD BILLION)
  • TABLE 229 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER LARGE MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 230 EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER LARGE MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 231 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER LARGE MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 232 LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER LARGE MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 233 MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER LARGE MOLECULES, BY REGION, 2023–2030 (USD BILLION)
  • TABLE 234 GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER LARGE MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 235 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2023–2030 (USD BILLION)
  • TABLE 236 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIG PHARMACEUTICAL COMPANIES, BY REGION, 2023–2030 (USD BILLION)
  • TABLE 237 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIG PHARMACEUTICAL COMPANIES, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 238 EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIG PHARMACEUTICAL COMPANIES, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 239 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIG PHARMACEUTICAL COMPANIES, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 240 LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIG PHARMACEUTICAL COMPANIES, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 241 MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIG PHARMACEUTICAL COMPANIES, BY REGION, 2023–2030 (USD BILLION)
  • TABLE 242 GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIG PHARMACEUTICAL COMPANIES, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 243 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES, BY REGION, 2023–2030 (USD BILLION)
  • TABLE 244 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 245 EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 246 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 247 LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 248 MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES, BY REGION, 2023–2030 (USD BILLION)
  • TABLE 249 GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 250 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR GENERIC PHARMACEUTICAL COMPANIES, BY REGION, 2023–2030 (USD BILLION)
  • TABLE 251 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKETFOR GENERIC PHARMACEUTICAL COMPANIES, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 252 EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR GENERIC PHARMACEUTICAL COMPANIES, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 253 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR GENERIC PHARMACEUTICAL COMPANIES, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 254 LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR GENERIC PHARMACEUTICAL COMPANIES, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 255 MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR GENERIC PHARMACEUTICAL COMPANIES, BY REGION, 2023–2030 (USD BILLION)
  • TABLE 256 GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR GENERIC PHARMACEUTICAL COMPANIES, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 257 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER END USERS, BY REGION, 2023–2030 (USD BILLION)
  • TABLE 258 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 259 EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 260 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 261 LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 262 MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER END USERS, BY REGION, 2023–2030 (USD BILLION)
  • TABLE 263 GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 264 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY REGION, 2023–2030 (USD BILLION)
  • TABLE 265 NORTH AMERICA: KEY MACROECONOMIC INDICATORS
  • TABLE 266 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 267 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD BILLION)
  • TABLE 268 NORTH AMERICA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 269 NORTH AMERICA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 270 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 271 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE, 2023–2030 (USD BILLION)
  • TABLE 272 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 273 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 274 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2023–2030 (USD BILLION)
  • TABLE 275 US: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD BILLION)
  • TABLE 276 US: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 277 US: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 278 US: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 279 US: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE, 2023–2030 (USD BILLION)
  • TABLE 280 US: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 281 US: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 282 US: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2023–2030 (USD BILLION)
  • TABLE 283 CANADA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD BILLION)
  • TABLE 284 CANADA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 285 CANADA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 286 CANADA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 287 CANADA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE, 2023–2030 (USD BILLION)
  • TABLE 288 CANADA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 289 CANADA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 290 CANADA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2023–2030 (USD BILLION)
  • TABLE 291 EUROPE: KEY MACROECONOMIC INDICATORS
  • TABLE 292 EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 293 EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD BILLION)
  • TABLE 294 EUROPE: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 295 EUROPE: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 296 EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 297 EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE, 2023–2030 (USD BILLION)
  • TABLE 298 EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 299 EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 300 EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2023–2030 (USD BILLION)
  • TABLE 301 GERMANY: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD BILLION)
  • TABLE 302 GERMANY: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 303 GERMANY: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 304 GERMANY: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 305 GERMANY: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE, 2023–2030 (USD BILLION)
  • TABLE 306 GERMANY: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 307 GERMANY: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 308 GERMANY: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2023–2030 (USD BILLION)
  • TABLE 309 UK: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD BILLION)
  • TABLE 310 UK: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 311 UK: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 312 UK: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 313 UK: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE, 2023–2030 (USD BILLION)
  • TABLE 314 UK: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 315 UK: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 316 UK: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2023–2030 (USD BILLION)
  • TABLE 317 FRANCE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD BILLION)
  • TABLE 318 FRANCE: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 319 FRANCE: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 320 FRANCE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 321 FRANCE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE, 2023–2030 (USD BILLION)
  • TABLE 322 FRANCE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 323 FRANCE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 324 FRANCE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2023–2030 (USD BILLION)
  • TABLE 325 ITALY: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD BILLION)
  • TABLE 326 ITALY: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 327 ITALY: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 328 ITALY: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 329 ITALY: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE, 2023–2030 (USD BILLION)
  • TABLE 330 ITALY: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 331 ITALY: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 332 ITALY: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2023–2030 (USD BILLION)
  • TABLE 333 SWITZERLAND: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD BILLION)
  • TABLE 334 SWITZERLAND: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 335 SWITZERLAND: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET,BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 336 SWITZERLAND: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 337 SWITZERLAND: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE, 2023–2030 (USD BILLION)
  • TABLE 338 SWITZERLAND: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 339 SWITZERLAND: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 340 SWITZERLAND: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2023–2030 (USD BILLION)
  • TABLE 341 POLAND: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD BILLION)
  • TABLE 342 POLAND: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 343 POLAND: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 344 POLAND: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 345 POLAND: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE, 2023–2030 (USD BILLION)
  • TABLE 346 POLAND: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 347 POLAND: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 348 POLAND: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2023–2030 (USD BILLION)
  • TABLE 349 SPAIN: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD BILLION)
  • TABLE 350 SPAIN: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 351 SPAIN: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 352 SPAIN: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 353 SPAIN: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE, 2023–2030 (USD BILLION)
  • TABLE 354 SPAIN: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 355 SPAIN: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 356 SPAIN: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2023–2030 (USD BILLION)
  • TABLE 357 REST OF EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD BILLION)
  • TABLE 358 REST OF EUROPE: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 359 REST OF EUROPE: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 360 REST OF EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 361 REST OF EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE, 2023–2030 (USD BILLION)
  • TABLE 362 REST OF EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 363 REST OF EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 364 REST OF EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2023–2030 (USD BILLION)
  • TABLE 365 ASIA PACIFIC: KEY MACROECONOMIC INDICATORS
  • TABLE 366 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 367 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD BILLION)
  • TABLE 368 ASIA PACIFIC: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 369 ASIA PACIFIC: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 370 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 371 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE, 2023–2030 (USD BILLION)
  • TABLE 372 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 373 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 374 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2023–2030 (USD BILLION)
  • TABLE 375 CHINA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD BILLION)
  • TABLE 376 CHINA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 377 CHINA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 378 CHINA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 379 CHINA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE, 2023–2030 (USD BILLION)
  • TABLE 380 CHINA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 381 CHINA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 382 CHINA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2023–2030 (USD BILLION)
  • TABLE 383 JAPAN: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD BILLION)
  • TABLE 384 JAPAN: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 385 JAPAN: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 386 JAPAN: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 387 JAPAN: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE, 2023–2030 (USD BILLION)
  • TABLE 388 JAPAN: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 389 JAPAN: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 390 JAPAN: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2023–2030 (USD BILLION)
  • TABLE 391 SOUTH KOREA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD BILLION)
  • TABLE 392 SOUTH KOREA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 393 SOUTH KOREA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 394 SOUTH KOREA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 395 SOUTH KOREA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE, 2023–2030 (USD BILLION)
  • TABLE 396 SOUTH KOREA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 397 SOUTH KOREA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 398 SOUTH KOREA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2023–2030 (USD BILLION)
  • TABLE 399 INDIA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD BILLION)
  • TABLE 400 INDIA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 401 INDIA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 402 INDIA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 403 INDIA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE, 2023–2030 (USD BILLION)
  • TABLE 404 INDIA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 405 INDIA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 406 INDIA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2023–2030 (USD BILLION)
  • TABLE 407 AUSTRALIA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD BILLION)
  • TABLE 408 AUSTRALIA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 409 AUSTRALIA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 410 AUSTRALIA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 411 AUSTRALIA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE, 2023–2030 (USD BILLION)
  • TABLE 412 AUSTRALIA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 413 AUSTRALIA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 414 AUSTRALIA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2023–2030 (USD BILLION)
  • TABLE 415 REST OF ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD BILLION)
  • TABLE 416 REST OF ASIA PACIFIC: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 417 REST OF ASIA PACIFIC: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 418 REST OF ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 419 REST OF ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE, 2023–2030 (USD BILLION)
  • TABLE 420 REST OF ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 421 REST OF ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 422 REST OF ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2023–2030 (USD BILLION)
  • TABLE 423 LATIN AMERICA: KEY MACROECONOMIC INDICATORS
  • TABLE 424 LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 425 LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD BILLION)
  • TABLE 426 LATIN AMERICA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 427 LATIN AMERICA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 428 LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 429 LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE, 2023–2030 (USD BILLION)
  • TABLE 430 LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 431 LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 432 LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2023–2030 (USD BILLION)
  • TABLE 433 BRAZIL: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD BILLION)
  • TABLE 434 BRAZIL: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 435 BRAZIL: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 436 BRAZIL: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 437 BRAZIL: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE, 2023–2030 (USD BILLION)
  • TABLE 438 BRAZIL: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 439 BRAZIL: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 440 BRAZIL: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2023–2030 (USD BILLION)
  • TABLE 441 MEXICO: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD BILLION)
  • TABLE 442 MEXICO: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 443 MEXICO: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 444 MEXICO: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 445 MEXICO: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE, 2023–2030 (USD BILLION)
  • TABLE 446 MEXICO: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 447 MEXICO: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 448 MEXICO: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2023–2030 (USD BILLION)
  • TABLE 449 REST OF LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD BILLION)
  • TABLE 450 REST OF LATIN AMERICA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 451 REST OF LATIN AMERICA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 452 REST OF LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 453 REST OF LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE, 2023–2030 (USD BILLION)
  • TABLE 454 REST OF LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 455 REST OF LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 456 REST OF LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2023–2030 (USD BILLION)
  • TABLE 457 MIDDLE EAST: KEY MACROECONOMIC INDICATORS
  • TABLE 458 MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY REGION, 2023–2030 (USD BILLION)
  • TABLE 459 MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD BILLION)
  • TABLE 460 MIDDLE EAST: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 461 MIDDLE EAST: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 462 MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 463 MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE, 2023–2030 (USD BILLION)
  • TABLE 464 MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 465 MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 466 MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2023–2030 (USD BILLION)
  • TABLE 467 GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
  • TABLE 468 GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD BILLION)
  • TABLE 469 GCC COUNTRIES: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 470 GCC COUNTRIES: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 471 GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 472 GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE, 2023–2030 (USD BILLION)
  • TABLE 473 GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 474 GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 475 GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2023–2030 (USD BILLION)
  • TABLE 476 KINGDOM OF SAUDI ARABIA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD BILLION)
  • TABLE 477 KINGDOM OF SAUDI ARABIA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 478 KINGDOM OF SAUDI ARABIA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 479 KINGDOM OF SAUDI ARABIA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 480 KINGDOM OF SAUDI ARABIA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE, 2023–2030 (USD BILLION)
  • TABLE 481 KINGDOM OF SAUDI ARABIA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 482 KINGDOM OF SAUDI ARABIA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 483 KINGDOM OF SAUDI ARABIA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2023–2030 (USD BILLION)
  • TABLE 484 UAE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD BILLION)
  • TABLE 485 UAE: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 486 UAE: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 487 UAE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 488 UAE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE, 2023–2030 (USD BILLION)
  • TABLE 489 UAE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 490 UAE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 491 UAE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2023–2030 (USD BILLION)
  • TABLE 492 REST OF GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD BILLION)
  • TABLE 493 REST OF GCC COUNTRIES: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 494 REST OF GCC COUNTRIES: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 495 REST OF GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 496 REST OF GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE, 2023–2030 (USD BILLION)
  • TABLE 497 REST OF GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 498 REST OF GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 499 REST OF GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2023–2030 (USD BILLION)
  • TABLE 500 REST OF MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD BILLION)
  • TABLE 501 REST OF MIDDLE EAST: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 502 REST OF MIDDLE EAST: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 503 REST OF MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 504 REST OF MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE, 2023–2030 (USD BILLION)
  • TABLE 505 REST OF MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 506 REST OF MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 507 REST OF MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2023–2030 (USD BILLION)
  • TABLE 508 AFRICA: KEY MACROECONOMIC INDICATORS
  • TABLE 509 AFRICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD BILLION)
  • TABLE 510 AFRICA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 511 AFRICA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 512 AFRICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 513 AFRICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE, 2023–2030 (USD BILLION)
  • TABLE 514 AFRICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 515 AFRICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
  • TABLE 516 AFRICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2023–2030 (USD BILLION) S
  • TABLE 517 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, JANUARY 2022–AUGUST 2025
  • TABLE 518 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: DEGREE OF COMPETITION
  • TABLE 519 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: REGION FOOTPRINT
  • TABLE 520 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: SERVICE FOOTPRINT
  • TABLE 521 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: MOLECULE FOOTPRINT
  • TABLE 522 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: DETAILED LIST OF KEY STARTUPS/SMES
  • TABLE 523 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
  • TABLE 524 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: SERVICE LAUNCHES, JANUARY 2022–JULY 2025
  • TABLE 525 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: DEALS, JANUARY 2022–JULY 2025
  • TABLE 526 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: EXPANSIONS,JANUARY 2022–JULY 2025
  • TABLE 527 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
  • TABLE 528 THERMO FISHER SCIENTIFIC INC.: SERVICES OFFERED
  • TABLE 529 THERMO FISHER SCIENTIFIC INC.: SERVICE LAUNCHES, JANUARY 2022–JULY 2025
  • TABLE 530 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2022–JULY 2025
  • TABLE 531 LONZA: COMPANY OVERVIEW
  • TABLE 532 LONZA: SERVICES OFFERED
  • TABLE 533 LONZA: DEALS, JANUARY 2022–JULY 2025
  • TABLE 534 LONZA: EXPANSIONS, JANUARY 2022–JULY 2025
  • TABLE 535 CATALENT, INC.: COMPANY OVERVIEW
  • TABLE 536 CATALENT, INC.: SERVICES OFFERED
  • TABLE 537 CATALENT, INC.: SERVICE LAUNCHES, JANUARY 2022–JULY 2025
  • TABLE 538 CATALENT, INC.: DEALS, JANUARY 2022–JULY 2025
  • TABLE 539 CATALENT, INC.: EXPANSIONS, JANUARY 2022–JULY 2025
  • TABLE 540 WUXI APPTEC: COMPANY OVERVIEW
  • TABLE 541 WUXI APPTEC: SERVICES OFFERED
  • TABLE 542 WUXI APPTEC: DEALS, JANUARY 2022–JULY 2025
  • TABLE 543 WUXI APPTEC: EXPANSIONS, JANUARY 2022–JULY 2025
  • TABLE 544 WUXI BIOLOGICS: COMPANY OVERVIEW
  • TABLE 545 WUXI BIOLOGICS: SERVICES OFFERED
  • TABLE 546 WUXI BIOLOGICS: SERVICE LAUNCHES, JANUARY 2022–JULY 2025
  • TABLE 547 WUXI BIOLOGICS: DEALS, JANUARY 2022–JULY 2025
  • TABLE 548 WUXI BIOLOGICS: EXPANSIONS, JANUARY 2022–JULY 2025
  • TABLE 549 WUXI BIOLOGICS: OTHER DEVELOPMENTS, JANUARY 2022–JULY 2025
  • TABLE 550 SAMSUNG BIOLOGICS: COMPANY OVERVIEW
  • TABLE 551 SAMSUNG BIOLOGICS: SERVICES OFFERED
  • TABLE 552 SAMSUNG BIOLOGICS: SERVICE LAUNCHES, JANUARY 2022–JUNE 2025
  • TABLE 553 SAMSUNG BIOLOGICS: DEALS, JANUARY 2022–JULY 2025
  • TABLE 554 SAMSUNG BIOLOGICS: EXPANSIONS, JANUARY 2022–JULY 2025
  • TABLE 555 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY OVERVIEW
  • TABLE 556 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: SERVICES OFFERED
  • TABLE 557 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: DEALS, JANUARY 2022–JULY 2025
  • TABLE 558 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: EXPANSIONS, JANUARY 2022–JULY 2025
  • TABLE 559 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: OTHER DEVELOPMENTS, JANUARY 2022–JULY 2025
  • TABLE 560 EVONIK: COMPANY OVERVIEW
  • TABLE 561 EVONIK: SERVICES OFFERED
  • TABLE 562 EVONIK: DEALS, JANUARY 2022–JULY 2025
  • TABLE 563 EVONIK: EXPANSIONS, JANUARY 2022–JULY 2025
  • TABLE 564 FUJIFILM HOLDINGS CORPORATION: COMPANY OVERVIEW
  • TABLE 565 FUJIFILM HOLDINGS CORPORATION: SERVICES OFFERED
  • TABLE 566 FUJIFILM HOLDINGS CORPORATION: DEALS, JANUARY 2022–JULY 2025
  • TABLE 567 FUJIFILM HOLDINGS CORPORATION: EXPANSIONS, JANUARY 2022–JULY 2025
  • TABLE 568 ABBVIE INC.: COMPANY OVERVIEW
  • TABLE 569 ABBVIE INC.: SERVICES OFFERED
  • TABLE 570 ABBVIE INC.: DEALS, JANUARY 2022–JULY 2025
  • TABLE 571 ABBVIE INC.: EXPANSIONS, JANUARY 2022–JULY 2025
  • TABLE 572 SIEGFRIED HOLDING AG: COMPANY OVERVIEW
  • TABLE 573 SIEGFRIED HOLDING AG: SERVICES OFFERED
  • TABLE 574 SIEGFRIED HOLDING AG: DEALS, JANUARY 2022–JULY 2025
  • TABLE 575 SIEGFRIED HOLDING AG: EXPANSIONS, JANUARY 2022–JULY 2025
  • TABLE 576 MERCK KGAA: COMPANY OVERVIEW
  • TABLE 577 MERCK KGAA: SERVICES OFFERED
  • TABLE 578 MERCK KGAA: DEALS, JANUARY 2022–JULY 2025
  • TABLE 579 MERCK KGAA: EXPANSIONS, JANUARY 2022–JULY 2025
  • TABLE 580 ALMAC GROUP: COMPANY OVERVIEW
  • TABLE 581 ALMAC GROUP: SERVICES OFFERED
  • TABLE 582 ALMAC GROUP: DEALS, JANUARY 2022–JULY 2025
  • TABLE 583 ALMAC GROUP: EXPANSIONS, JANUARY 2022–JULY 2025
  • TABLE 584 CHARLES RIVER LABORATORIES: COMPANY OVERVIEW
  • TABLE 585 CHARLES RIVER LABORATORIES: SERVICES OFFERED
  • TABLE 586 CHARLES RIVER LABORATORIES: DEALS, JANUARY 2022–JULY 2025
  • TABLE 587 CHARLES RIVER LABORATORIES: EXPANSIONS, JANUARY 2022–JULY 2025
  • TABLE 588 ASYMCHEM INC.: COMPANY OVERVIEW
  • TABLE 589 ASYMCHEM INC.: SERVICES OFFERED
  • TABLE 590 ASYMCHEM INC.: DEALS, JANUARY 2022–JULY 2025
  • TABLE 591 ASYMCHEM INC.: EXPANSIONS, JANUARY 2022–JULY 2025
  • TABLE 592 VETTER: COMPANY OVERVIEW
  • TABLE 593 VETTER: SERVICES OFFERED
  • TABLE 594 VETTER: SERVICE LAUNCHES, JANUARY 2022–JULY 2025
  • TABLE 595 VETTER: DEALS, JANUARY 2022–JULY 2025
  • TABLE 596 VETTER: EXPANSIONS, JANUARY 2022–JULY 2025
  • TABLE 597 ALCAMI CORPORATION: COMPANY OVERVIEW
  • TABLE 598 ALCAMI CORPORATION: SERVICES OFFERED
  • TABLE 599 ALCAMI CORPORATION: DEALS, JANUARY 2022–JULY 2025
  • TABLE 600 ALCAMI CORPORATION: EXPANSIONS, JANUARY 2022–JULY 2025
  • TABLE 601 EUROFINS SCIENTIFIC: COMPANY OVERVIEW
  • TABLE 602 EUROFINS SCIENTIFIC: SERVICES OFFERED
  • TABLE 603 EUROFINS SCIENTIFIC: EXPANSIONS, JANUARY 2022–JUNE 2025
  • TABLE 604 PIRAMAL PHARMA SOLUTIONS: COMPANY OVERVIEW
  • TABLE 605 SYNGENE INTERNATIONAL LIMITED: COMPANY OVERVIEW
  • TABLE 606 CAMBREX CORPORATION: COMPANY OVERVIEW
  • TABLE 607 JUBILANT PHARMANOVA LIMITED: COMPANY OVERVIEW
  • TABLE 608 YUHAN CORPORATION: COMPANY OVERVIEW
  • TABLE 609 PIERRE FABRE LABORATORIES: COMPANY OVERVIEW
  • TABLE 610 PFIZER CENTREONE: COMPANY OVERVIEW
  • TABLE 611 DELPHARM: COMPANY OVERVIEW
  • TABLE 612 FRONTAGE LABS: COMPANY OVERVIEW
  • TABLE 613 SHARP SERVICES, LLC: COMPANY OVERVIEW
  • TABLE 614 GRAND RIVER ASEPTIC MANUFACTURING: COMPANY OVERVIEW
  • TABLE 615 RECIPHARM AB: COMPANY OVERVIEW
  • TABLE 616 PCI PHARMA SERVICES: COMPANY OVERVIEW
  • TABLE 617 CURIA GLOBAL, INC.: COMPANY OVERVIEW
  • TABLE 618 SIMTRA BIOPHARMA SOLUTIONS: COMPANY OVERVIEW
  • TABLE 619 PORTON: COMPANY OVERVIEW
  • TABLE 620 MABPLEX INTERNATIONAL CO. LTD.: COMPANY OVERVIEW
  • TABLE 621 CELLARES: COMPANY OVERVIEW
LIST OF FIGURES
 
  • FIGURE 1 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SEGMENTATION AND REGIONAL SCOPE
  • FIGURE 2 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: YEARS CONSIDERED
  • FIGURE 3 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: RESEARCH DESIGN
  • FIGURE 4 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: KEY DATA FROM SECONDARY SOURCES
  • FIGURE 5 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: BREAKDOWN OF PRIMARY INTERVIEWS
  • FIGURE 6 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2024
  • FIGURE 7 COMPANY REVENUE ANALYSIS-BASED ESTIMATION: BOTTOM-UP APPROACH, 2024
  • FIGURE 8 REVENUE SHARE ANALYSIS OF THERMO FISHER SCIENTIFIC INC., 2024
  • FIGURE 9 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE VALIDATION FROM PRIMARY SOURCES
  • FIGURE 10 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: TOP-DOWN APPROACH
  • FIGURE 11 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: CAGR PROJECTIONS
  • FIGURE 12 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: DATA TRIANGULATION
  • FIGURE 13 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2025 VS. 2030 (USD BILLION)
  • FIGURE 14 PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2025 VS. 2030 (USD BILLION)
  • FIGURE 15 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE, 2025 VS. 2030 (USD BILLION)
  • FIGURE 16 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2025 VS. 2030 (USD BILLION)
  • FIGURE 17 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY REGION, 2025–2030
  • FIGURE 18 RISING INVESTMENTS IN PHARMACEUTICAL R&D TO DRIVE MARKET
  • FIGURE 19 PHARMACEUTICAL MANUFACTURING SERVICES AND US TO LEAD NORTH AMERICAN MARKET IN 2025
  • FIGURE 20 SMALL MOLECULES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
  • FIGURE 21 BIG PHARMACEUTICAL COMPANIES SEGMENT TO ACCOUNT FOR LARGEST MARKET SHARE DURING FORECAST PERIOD
  • FIGURE 22 CHINA TO HAVE LARGEST MARKET DURING FORECAST PERIOD
  • FIGURE 23 EMERGING MARKETS TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD
  • FIGURE 24 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 25 NEW REVENUE POCKETS FOR PLAYERS IN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET
  • FIGURE 26 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: VALUE CHAIN ANALYSIS
  • FIGURE 27 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: SUPPLY CHAIN ANALYSIS
  • FIGURE 28 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: ECOSYSTEM ANALYSIS
  • FIGURE 29 INVESTMENT AND FUNDING SCENARIO, 2023–2024
  • FIGURE 30 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: PATENT ANALYSIS, JANUARY 2014–DECEMBER 2024
  • FIGURE 31 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: PORTER’S FIVE FORCES ANALYSIS
  • FIGURE 32 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY SERVICE
  • FIGURE 33 KEY BUYING CRITERIA FOR END USERS
  • FIGURE 34 ABBREVIATED NEW DRUG APPLICATION (ANDA) APPROVALS, 2020–2025
  • FIGURE 35 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: AI USE CASES
  • FIGURE 36 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SNAPSHOT
  • FIGURE 37 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SNAPSHOT
  • FIGURE 39 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SHARE ANALYSIS OF KEY PLAYERS, 2024
  • FIGURE 40 EV/EBITDA OF KEY VENDORS
  • FIGURE 41 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
  • FIGURE 42 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: BRAND/SERVICE COMPARISON
  • FIGURE 43 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024
  • FIGURE 44 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: COMPANY FOOTPRINT
  • FIGURE 45 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024
  • FIGURE 46 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2024)
  • FIGURE 47 LONZA: COMPANY SNAPSHOT (2024)
  • FIGURE 48 CATALENT, INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 49 WUXI APPTEC: COMPANY SNAPSHOT (2024)
  • FIGURE 50 WUXI BIOLOGICS: COMPANY SNAPSHOT (2024)
  • FIGURE 51 SAMSUNG BIOLOGICS: COMPANY SNAPSHOT (2024)
  • FIGURE 52 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY SNAPSHOT (2024)
  • FIGURE 53 EVONIK: COMPANY SNAPSHOT (2024)
  • FIGURE 54 FUJIFILM HOLDINGS CORPORATION: COMPANY SNAPSHOT (2024)
  • FIGURE 55 ABBVIE INC.: COMPANY SNAPSHOT (2024)
  • FIGURE 56 SIEGFRIED HOLDING AG: COMPANY SNAPSHOT (2024)
  • FIGURE 57 MERCK KGAA: COMPANY SNAPSHOT (2024)
  • FIGURE 58 ALMAC GROUP: COMPANY SNAPSHOT (2024)
  • FIGURE 59 CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT (2024)
  • FIGURE 60 ASYMCHEM INC.: COMPANY SNAPSHOT (2024)
  • FIGURE 61 VETTER: COMPANY SNAPSHOT (2024)
  • FIGURE 62 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2024)

Methodology

This research study extensively used secondary sources, directories, and databases to identify and collect valuable information to analyze the global pharmaceutical contract manufacturing market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess the growth prospects of the market. The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.

Secondary Research

Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the pharmaceutical contract manufacturing market. The secondary sources used for this study include Indian Pharmaceutical Association (IPA), Pharmaceutical Research and Manufacturers of America (PhRMA), European Federation of Pharmaceutical Industries and Associations (EFPIA), Central Drugs Standard Control Organization (CDSCO), Indian Brand Equity Foundation (IBEF), European Medicines Agency (EMA), Pharma & Biopharma Outsourcing Association (PBOA), Generics and Biosimilars Initiative (GaBI), Pharma Times, Parenteral Drug Association (PDA), Indian Drug Manufacturers’ Association (IDMA), American Association of Pharmaceutical Scientists (AAPS), Global Cancer Observatory, American Chemical Society, National Center for Biotechnology Information, Eurostat, Food and Drug Administration (FDA), Biotechnology and Biological Sciences Research Council (BBSRC), Pharmaceutical Research and Manufacturers of America (PhRMA), World Journal of Pharmaceutical Sciences, research journals; corporate filings such as annual reports, SEC filings, investor presentations, and financial statements; press releases; trade, business, professional associations and among others. These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.

Primary Research

Following an initial assessment of the global pharmaceutical contract manufacturing market landscape through secondary research, comprehensive primary research was undertaken. This involved conducting in-depth interviews with market experts from the demand side, including stakeholders from pharmaceutical and biotechnology firms, CROs, CMOs, and academic and research institutions. Additionally, interviews were held with key supply-side participants, such as C-suite and senior executives, product managers, and marketing and sales leaders from prominent manufacturers, distributors, and channel partners. The research covered six major geographical regions: North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. Approximately 70% of the primary interviews were conducted with supply-side participants, while 30% involved demand-side experts. Data collection methods included structured questionnaires, email correspondence, online surveys, personal interviews, and telephonic discussions to understand the market dynamics comprehensively.

The following is a breakdown of the primary respondents:

Pharmaceutical Contract Manufacturing Market

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

Both bottom-up and top-down approaches were used to estimate and validate the total size of the pharmaceutical contract manufacturing market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

  • A list of the major global players operating in the pharmaceutical contract manufacturing market was generated.
  • The revenues generated from their pharmaceutical contract manufacturing product have been determined through annual reports and secondary sources (including paid databases)
  • The products were mapped according to the segments of the market. Percentage shares and splits were determined based on the revenue contributed to each segment. This was verified using secondary sources and by industry experts.
  • All assumptions, approaches, and individual shares/revenue estimates were validated through interviews with experts.

Global Pharmaceutical Contract Manufacturing Market: Bottom-up and Top-down Approach

Pharmaceutical Contract Manufacturing Market

Data Triangulation

After arriving at the market size from the estimation process explained above, the total market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Market Definition

Pharmaceutical contract manufacturing organizations (CMOs) provide contract-based, comprehensive services, such as drug development and manufacturing. CMOs offer manufacturing services for active pharmaceutical ingredients (APIs) and finished dosage formulations (FDFs). Different aspects of contract manufacturing, such as drug development & manufacturing, formulation development, and commercial pharmaceutical & biopharmaceutical manufacturing, have been considered in this report.

Stakeholders

  • Contract Development & Manufacturing Organizations
  • Biotechnology and Pharmaceutical Companies
  • Academic and Research Institutions
  • Corporate Entities
  • Venture Capitalists
  • Regulatory Agencies
  • Industry Associations and Government Agencies
  • Pharmaceutical Distributors and Suppliers
  • Contract Research Organizations

Report Objectives

  • To define, describe, and forecast the global pharmaceutical contract manufacturing market based on the service, molecule, end user, and region
  • To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
  • To strategically analyze micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall pharmaceutical contract manufacturing market
  • To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
  • To forecast the size of the market segments with respect to six main regions: North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
  • To profile the key players in the pharmaceutical contract manufacturing market and comprehensively analyze their service portfolios, market positions, and core competencies
  • To track and analyze competitive developments in the pharmaceutical contract manufacturing market, such as acquisitions, product launches, expansions, agreements, partnerships, and collaborations
  • To benchmark players within the pharmaceutical contract manufacturing market using the ‘Company Evaluation Matrix' framework, which analyzes market players based on various parameters within the broad categories of business strategy and product strategy

 

TABLE OF CONTENTS

METHODOLOGY

Need a Tailored Report?

Customize this report to your needs

Get 10% FREE Customization

Customize This Report
Fact checked
Cite this Research

Adjacent Markets

Request Bundle Reports

Personalize This Research

  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
Request A Free Customisation

Let Us Help You

  • What are the Known and Unknown Adjacencies Impacting the Pharmaceutical Contract Manufacturing Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
Customized Workshop Request
Forbes

Custom Market Research Services

We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements

Get 10% Free Customisation

Growth opportunities and latent adjacency in Pharmaceutical Contract Manufacturing Market

Kahlill

Feb, 2023

What will be the key challenges for business in the pharmaceutical contract manufacturing market in the near future?.

MnM Analyst

Jul, 2023

Key players in pharmaceutical contract manufacturing industry for North America region include:

  • Pfizer
  • Merck & Co., Inc.
  • Boehringer Ingelheim
  • AbbVie Inc.
  • Roche
  • Novartis
  • GlaxoSmithKline
  • Sanofi
  • AstraZeneca
  • Eli Lilly and Company among others
.

James

Jul, 2023

Who are the top key players in the pharmaceutical contract manufacturing market in North America?.

DMCA.com Protection Status